Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization

doi:10.4254/wjh.v14.i6.1162

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2364)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

107

WORD

HTML

930

Figures (1-1)

272

Tables (1-3)

260

Sum=1608

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

223

Download

533

Sum=756

Jun 27, 2022 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jun 27, 2022; 14(6): 1162-1172
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1162

Impact of alcohol consumption on treatment outcome of hepatocellular carcinoma patients with viral hepatitis who underwent transarterial chemoembolization

Attapon Rattanasupar, Arunchai Chang, Tanaporn Prateepchaiboon, Nuttanit Pungpipattrakul, Keerati Akarapatima, Apiradee Songjamrat, Songklod Pakdeejit, Varayu Prachayakul, Teerha Piratvisuth

Attapon Rattanasupar, Arunchai Chang, Keerati Akarapatima, Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Hatyai 90110, Songkhla, Thailand

Tanaporn Prateepchaiboon, Nuttanit Pungpipattrakul, Department of Internal Medicine, Hatyai Hospital, Hatyai 90110, Songkhla, Thailand

Apiradee Songjamrat, Songklod Pakdeejit, Division of Intervention Radiology, Department of Radiology, Hatyai Hospital, Hatyai 90110, Songkhla, Thailand

Varayu Prachayakul, Siriraj Gastrointestinal Endoscopy Center, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkoknoi 10700, Bangkok, Thailand

Teerha Piratvisuth, NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Hatyai 90110, Songkhla, Thailand

Author contributions: Rattanasupar A designed and conceptualized the study, acquired the data and drafted the manuscript; Chang A designed and conceptualized the study, acquired, analyzed, and interpreted the data, and drafted the manuscript; Prateepchaiboon T designed and conceptualized the study, acquired, analyzed, and interpreted the data; Pungpipattrakul N, Akarapatima K, Songjamrat A, and Pakdeejit S acquired, analyzed, and interpreted the data; Prachayakul V and Piratvisuth T critically revised the manuscript for important intellectual content.

Institutional review board statement: The study was reviewed and approved for publication by the Institutional Review Board of Hatyai Hospital (protocol number HYH EC 105-64-01.

Informed consent statement: The need for informed consent was waived because the de-identification of patient information before analysis.

Conflict-of-interest statement: All the authors declare that they have no conflict of interest.

Data sharing statement: No additional data are available

STROBE statement: All the authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Arunchai Chang, MD, Assistant Professor, Doctor, Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, 182 Ruthakal road, Hatyai, Hatyai 90110, Songkhla, Thailand. busmdcu58@gmail.com

Received: February 4, 2022
Peer-review started: February 4, 2022
First decision: April 17, 2022
Revised: April 24, 2022
Accepted: June 13, 2022
Article in press: June 13, 2022
Published online: June 27, 2022

Core Tip

Core Tip: Regular alcohol consumption is associated with increased hepatocellular carcinoma (HCC) risk, particularly in patients with pre-existing chronic liver diseases, including viral hepatitis B and C infection. However, data on the impact of alcohol consumption on HCC outcomes after treatment with transarterial chemoembolization (TACE) remain limited. This study is the first to address the additional effect of alcohol on treatment outcomes of transarterial chemoembolization TACE among HCC patients with viral hepatitis.